Goldman Sachs
WINT

Goldman Sachs’s Windtree Therapeutics Inc WINT Stock Holding History

Goldman Sachs’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,926
Closed -$12K – 7513
2015
Q4 		$12K Sell
3,926
-176
-4% -$722 ﹤0.01% 6945
2015
Q3 		$17K Sell
4,102
-837
-17% -$5.54K ﹤0.01% 7075
2015
Q2 		$47K Sell
4,939
-386
-7% -$5.42K ﹤0.01% 6886
2015
Q1 		$89K Sell
5,325
-2,625
-33% -$51.7K ﹤0.01% 6471
2014
Q4 		$129K Sell
7,950
-1,914
-19% -$42.1K ﹤0.01% 6455
2014
Q3 		$254K Sell
9,864
-8
-0.1% -$193 ﹤0.01% 5930
2014
Q2 		$246K Buy
9,872
+2,714
+38% +$69.4K ﹤0.01% 6037
2014
Q1 		$215K Sell
7,158
-4,278
-37% -$144K ﹤0.01% 6022
2013
Q4 		$360K Sell
11,436
-419
-4% -$13.1K ﹤0.01% 5551
2013
Q3 		$325K Sell
11,855
-92
-0.8% -$2.23K ﹤0.01% 5510
2013
Q2 		$254K Buy
+11,947
New +$294K ﹤0.01% 5432

Other funds holding WINT

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs's WINT Position: Q1 2016 in Review

Goldman Sachs sold out of Windtree Therapeutics Inc (WINT) in Q1 2016, closing a stake of 3,926 shares — an estimated $12K sold.

Goldman Sachs first reported a position in WINT in Q2 2013 and held it in 11 quarters. The position peaked at $360K in Q4 2013. 34 funds tracked by Wall St. Rank hold WINT as of Q1 2016.

  • Goldman Sachs reported no remaining Windtree Therapeutics Inc position as of Q1 2016 after selling out during the quarter.
  • Goldman Sachs sold 3,926 Windtree Therapeutics Inc shares in Q1 2016, an estimated $12K.
  • Goldman Sachs first reported a position in Windtree Therapeutics Inc in Q2 2013 and held it in 11 quarters.
  • Goldman Sachs's Windtree Therapeutics Inc position peaked at $360K in Q4 2013.
  • 34 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q1 2016.

Based on Goldman Sachs's 13F filing for Q1 2016, filed 13 May 2016.